A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Locally advanced (stage IIIB, excluding patients who are candidates for chemo-radiotherapy or radical thoracic radiotherapy), metastatic (stage IV) or recurrent squamous non-small cell lung cancer (NSCLC)
- Histologically documented squamous NSCLC. Mixed tumors should be categorized according to the predominant cell type
- Histological tumor tissue sample from initial diagnosis or new tumor biopsy representative of the disease
- Patients who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least 3 months prior to enrollment
- At least one measurable disease lesion as per RECIST 1.1 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Adequate hematological, liver and renal function
- Females of childbearing potential must commit to using a reliable and appropriate method of contraception until at least 3 months after the end of the last dose of study treatment
Exclusion Criteria:
- Prior chemotherapy (excluding neoadjuvant/adjuvant chemotherapy/chemo-radiotherapy) or treatment with another systemic anti-cancer agent (e.g. monoclonal antibody, tyrosine kinase inhibitor)
- Radiotherapy within the last 4 weeks prior to first dosing, except for limited field palliative radiotherapy for bone pain relief
- Treatment with any other investigational agent within 30 days prior to starting study treatment or participation in another clinical trial (e.g. CTC blood collection) within 7 days prior to starting study treatment
- Historical or clinical evidence of central nervous system (CNS) metastases (except for previously treated CNS metastases in patients that are asymptomatic, have had no evidence of active CNS metastases for >/= 3 months prior to first dose and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days)
- Recent history of poorly controlled hypertension (systolic >180 mmHg or diastolic >100 mmHg)
- Severe uncontrolled illness, including poorly controlled diabetes mellitus and active or uncontrolled infection
- Hypersensitivity to the active substance or to any excipients or to any of the study drugs including premedication (corticosteroids, anti-histamine, paracetamol)
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: RO5083945 + carboplatin + paclitaxel
|
multiple ascending doses
up to 6 cycles
up to 6 cycles
|
|
Experimental: RO5083945 + cisplatin +gemcitabine
|
multiple ascending doses
up to 6 cycles
up to 6 cycles
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum tolerated dose in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
Time Frame: approximately 1.5 years
|
approximately 1.5 years
|
|
Recommended phase II dose (RP2D) of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
Time Frame: approximately 1.5 years
|
approximately 1.5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety: Incidence of adverse events
Time Frame: approximately 1.5 years
|
approximately 1.5 years
|
|
Pharmacokinetics: Serum concentrations of RO5083945 in combination with cisplatin and gemcitabine or carboplatin and paclitaxel
Time Frame: up to 18 weeks
|
up to 18 weeks
|
|
Pharmacokinetics: Effect of RO5083945 on serum concentrations of cisplatin
Time Frame: up to 18 weeks
|
up to 18 weeks
|
|
Pharmacokinetics: Effect of RO5083945 on serum concentrations of gemcitabine
Time Frame: up to 18 weeks
|
up to 18 weeks
|
|
Pharmacokinetics: Effect of RO5083945 on serum concentrations of carboplatin
Time Frame: up to 18 weeks
|
up to 18 weeks
|
|
Pharmacokinetics: Effect of RO5083945 on serum concentrations of paclitaxel
Time Frame: up to 18 weeks
|
up to 18 weeks
|
|
Preliminary evidence of antitumor activity: Objective response rate (complete response, partial response and stable disease)
Time Frame: approximately 1.5 years
|
approximately 1.5 years
|
|
Duration of response
Time Frame: approximately 1.5 years
|
approximately 1.5 years
|
|
Biomarker assessments : Immune effector cells/EGFR markers
Time Frame: up to 18 weeks
|
up to 18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neoplastic Processes
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Gemcitabine
- Carboplatin
- Paclitaxel
- Cisplatin
Other Study ID Numbers
Other Study ID Numbers
- BP28577
- 2012-003376-39 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.